Arch Biopartners Inc. (ACHFF)
| Previous Close | 1.5700 |
| Open | 1.5400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.5000 - 1.5450 |
| 52 Week Range | 1.4730 - 3.3800 |
| Volume | |
| Avg. Volume | 5,728 |
| Market Cap | 93.785M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 |
- GlobeNewswire
Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease
TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and
- GlobeNewswire
Shares for Interest Debt Settlement; Grants Options
TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements (the “Notes”). The shares for debt settlement is pending final approval from the TSX Venture Exchange (T
- GlobeNewswire
Arch Biopartners Adds Farris Smith as a Strategic Advisor
TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith of Novo Nordisk Canada Inc as a Strategic Advisor for general corporate activity and business development of the Company’s drug candidates. Mr. Farris Smith started his career with AP Moller in 2001 and jo
